BCM
JUNO

Bourgeon Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Bourgeon Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,600
Closed -$251K – 101
2016
Q1 		$251K Buy
+6,600
New +$230K 0.17% 75

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bourgeon Capital Management's JUNO Position: Q2 2016 in Review

Bourgeon Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2016, closing a stake of 6,600 shares — an estimated $251K sold.

Bourgeon Capital Management first reported a position in JUNO in Q1 2016 and held it in 1 quarter. The position peaked at $251K in Q1 2016. 170 funds tracked by Wall St. Rank hold JUNO as of Q2 2016.

  • Bourgeon Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Bourgeon Capital Management sold 6,600 Juno Therapeutics, Inc. shares in Q2 2016, an estimated $251K.
  • Bourgeon Capital Management first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 1 quarter.
  • Bourgeon Capital Management's Juno Therapeutics, Inc. position peaked at $251K in Q1 2016.
  • 170 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2016.

Based on Bourgeon Capital Management's 13F filing for Q2 2016, filed 2 Aug 2016.